Innovative treatments for multiple myeloma in adults who are not candidates for stem transplantation

In the reviewed article, we evaluated the different innovative therapeutic options for the treatment of multiple myeloma in patients who are not candidates for stem cell transplantation. Multiple myeloma (MM) is a malignant neoplasm whose incidence is increasing in developed countries. It represents around 1% of neoplastic diseases and 13% of hematologic cancers. It arises from an asymptomatic proliferation of premalignant monoclonal plasma cells derived from B cells after they pass through the germinal center stage in various genetic steps and microenvironmental changes. Although in this study we discuss various therapeutic options that seem promising, we must keep in mind that these still require further research for their application in order to reduce the adverse effects that some of them may present.